Related Experiment Videos
[20 years of cardiovascular epidemiology. The clinician's viewpoint]
1Service de Cardiologie B et Hémodynamique, Hôpital Cardiologique, Lille.
Revue D'Epidemiologie Et De Sante Publique
|November 1, 1996
Abstract:
Over the last twenty years, several important clinical trials have brought major advances in the field of prevention and treatment of cardiovascular diseases. Fibrinolytic drugs, ACE inhibitors, new antiplatelet drugs or new tools in the field of interventional cardiology have been studied and have changed the daily practice of the cardiologists. Several remarks and comments are proposed with regards of these trials.
Insights
Major clinical trials over twenty years have advanced cardiovascular disease prevention and treatment. New drugs and interventional cardiology tools have significantly changed medical practice.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Context:
- Cardiovascular diseases represent a significant global health burden.
- Medical practice in cardiology has evolved substantially over the past two decades.
- Numerous clinical trials have investigated novel therapeutic strategies.
Purpose:
- To review major clinical trials in cardiovascular disease prevention and treatment.
- To highlight key advancements and their impact on clinical practice.
- To provide commentary on the significance of these trials.
Summary:
- Significant progress in cardiovascular disease management has been achieved through pivotal clinical trials.
- Key advancements include the development of fibrinolytic drugs, ACE inhibitors, novel antiplatelet agents, and interventional cardiology techniques.
- These innovations have demonstrably altered the daily practice of cardiologists worldwide.
Impact:
- Improved patient outcomes in cardiovascular disease prevention and treatment.
- Enhanced understanding of pharmacological and interventional approaches.
- Shift in clinical paradigms for managing heart conditions.